Form D · Biotechnology
ReVision Therapeutics, Inc.
La Jolla, CA · CIK 0001489829
Offering snapshot reported Dec 20, 2011 · SEC filing
- Reported sold
- $500K Offering amount: $5M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 5, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 20, 2011 | Initial | $500,000 | No comparison | 2 | SEC filing |
| Apr 23, 2010 | Initial | $562,039 | No comparison | 23 | SEC filing |
| Apr 23, 2010 | Initial | $2,308,332 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-170338
Source: Form D, filed Dec 20, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Douglas Downs | Executive |
| Kevin Kinsella | Director |
| Jay Lichter, Ph.D. | Director, Executive |
| Nathan Mata | Executive |
| David Weber | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
11099 North Torrey Pines Road, Suite 290
La Jolla, CA, 92037
La Jolla, CA, 92037